Linagliptin/Metformin Stada (Metformin Hydrochloride, Linagliptin)

Linagliptin, the active ingredient in Linagliptin/Metformin Stada, is a DPP‑4 inhibitor presented as a fixed‑dose oral tablet for oral use. It is combined with metformin hydrochloride, a biguanide, to improve glycaemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Linagliptin/Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution, supporting timely delivery across multiple regions while ensuring product integrity.

Linagliptin/Metformin Stada is indicated for the management of type 2 diabetes mellitus, acting on glucose regulation pathways.

- Type 2 diabetes mellitus: improves overall glycaemic control when added to diet and exercise. - Inadequate control on metformin alone: provides additional DPP‑4 inhibition to lower HbA1c. - Combination with insulin: may reduce the required insulin dose while maintaining target glucose levels.

Adverse reactions may occur with Linagliptin/Metformin Stada and are reported in clinical use.

Common Side Effects: - Nausea - Diarrhoea - Abdominal discomfort - Headache - Dizziness - Mild hypoglycaemia (especially with sulfonylureas or insulin)

Serious or Rare Side Effects: - Lactic acidosis - Severe hypoglycaemia - Acute pancreatitis - Allergic reactions such as rash, angio‑edema or anaphylaxis - Significant renal function decline - Hepatic failure

Before prescribing Linagliptin/Metformin Stada, clinicians should consider several safety aspects.

- Renal function assessment: evaluate eGFR prior to initiation and periodically thereafter. - Hepatic impairment: use with caution in patients with liver disease. - Risk of hypoglycaemia: monitor closely when combined with insulin or sulfonylureas. - Lactic acidosis risk: avoid in patients with conditions predisposing to hypoxia or severe renal impairment. - Pregnancy and lactation: assess risk–benefit before prescribing. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Linagliptin/Metformin Stada may interact with other medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Sulfonylureas or insulin: increased risk of severe hypoglycaemia. - Cimetidine: may raise linagliptin plasma concentrations. - Iodinated contrast agents: can impair renal function, necessitating temporary metformin discontinuation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycaemia. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function when used together.